Gene editing for immunological destruction of neoplasia
AssigneeBatu Biologics, Inc.
InventorsSamuel C. Wagner, Thomas Ichim
Life of this patent
Estimating the term…
Abstract
Disclosed are methods, protocols, and compositions of matter useful for induction and/or propagation of antitumor immune responses through gene editing of immunocytes. Stimulation of antitumor adaptive immunity is achieved through gene editing of autologous or allogeneic lymphocytes in a manner to derepress neoplasia induced suppression. The method can include targets of gene editing disclosed in the current invention include the E3 ubiquitin ligase Cb1-b, CTLA-4, PD-1, TIM-3, killer inhibitory receptor (KIR) and LAG-3.
Claims20
A method of treating cancer comprising the steps of:
- a) obtaining a cellular population containing lymphocytes;
- b) decreasing the ability of said lymphocytes to transcribe immune suppressive genes;
- and
- c) administering said lymphocytes into a patient suffering from cancer.
A genetically modified lymphocyte comprising a first vector, the first vector comprising a nucleic acid encoding a protein that deletes one or more immune checkpoint genes from the lymphocyte, wherein the one or more immune checkpoint genes is selected from the group consisting of E3 ubiquitin ligase Cb1-B, CTLA-4, PD-1, TIM-3, killer inhibitory receptor (KIR), LAG-3, CD73, Fas, aryl hydrocarbon receptor, Smad2, Smad4, TGF-beta receptor, and ILT-3.
Dependencies are inferred from the claim text.